XBIT

XBiotech Inc. NASDAQ Listed Apr 15, 2015

Healthcare ·Biotechnology ·US · xbiotech.com

$2.50

After hrs $2.50 +0.00%

Mkt Cap $76.2M

52w Low $2.09 27.0% of range 52w High $3.61

50d MA $2.39 200d MA $2.57

P/E (TTM) -1.7x

EV/EBITDA 1.0x

P/B 0.6x

Debt/Equity 0.0x

ROE -32.5%

P/FCF -1.8x

RSI (14) —

ATR (14) —

Beta 0.83

50d MA $2.39

200d MA $2.57

Avg Volume 37.1K

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.

SIC Code

2834

CIK (SEC)

1626878

Phone

512 386 2900

5217 Winnebago Lane · Austin, TX 78744 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 13, 2026	AMC	0.04	-0.88	-2300.0%	2.31	+0.4%	-0.4%	-2.2%	+0.0%	+4.4%	+1.7%	—
Nov 12, 2025	AMC	—	-0.20	—	2.77	-0.4%	-4.3%	-0.4%	-6.4%	-4.9%	-8.1%	—
Aug 13, 2025	AMC	—	-0.06	—	3.14	-1.0%	+3.2%	-2.8%	+1.6%	+0.3%	+0.3%	—
May 14, 2025	AMC	—	-0.36	—	2.88	-0.3%	+3.5%	+2.0%	+1.0%	-3.3%	-3.4%	—
Mar 18, 2025	AMC	—	-0.34	—	3.42	+0.9%	+1.8%	-0.9%	-0.3%	+0.6%	-4.6%	—
Nov 13, 2024	AMC	—	-0.16	—	7.10	+1.0%	-1.8%	-4.4%	+0.2%	+0.0%	-2.7%	—
Aug 12, 2024	AMC	—	-0.43	—	6.54	+0.6%	-1.7%	-3.0%	+2.1%	-4.7%	+6.1%	—
May 10, 2024	AMC	—	-0.33	—	8.31	+0.0%	+3.0%	+2.9%	-2.5%	-0.1%	-1.7%	—
Mar 15, 2024	AMC	—	-0.16	—	5.91	+0.5%	+12.2%	+7.2%	+0.7%	+1.3%	+3.4%	—
Nov 9, 2023	AMC	—	-0.24	—	3.83	+2.3%	+2.9%	-0.3%	-3.1%	-0.3%	-2.6%	—
Aug 11, 2023	AMC	—	-0.29	—	5.09	-3.1%	-3.1%	-1.6%	+0.2%	+5.1%	-2.2%	—
May 10, 2023	AMC	—	-0.13	—	3.29	+0.0%	+2.1%	-0.3%	-0.3%	+4.2%	+29.0%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 7	Piper Sandler	Maintains	Overweight → Overweight	—	$12.89	$12.99	+0.8%	-5.1%	+4.2%	+4.6%	+1.1%	+4.8%
Dec 11	Piper Sandler	Maintains	Overweight → Overweight	—	$18.89	$20.00	+5.8%	+2.6%	+2.0%	+0.5%	-1.9%	+2.1%
Dec 11	PiperJaffray	Maintains	Overweight → Overweight	—	$18.89	$20.00	+5.8%	+2.6%	+2.0%	+0.5%	-1.9%	+2.1%
Jun 14	Piper Jaffray	Maintains	Overweight → Overweight	—	$6.99	$7.24	+3.6%	+2.3%	+1.8%	+5.2%	-3.4%	-0.8%
Jun 14	Piper Sandler	Maintains	Overweight → Overweight	—	$6.99	$7.24	+3.6%	+2.3%	+1.8%	+5.2%	-3.4%	-0.8%

Data updated apr 24, 2026 11:42am · Source: massive.com